logo-loader

Arix sees significant potential as it ups stake in cancer treatment developer Artios

Published: 12:44 17 Aug 2018 BST

Jonathan Tobin, investment director at Arix Bioscience Plc (LON:ARIX), discusses with Proactive's Andrew Scott their decision to increase their stake and in doing so becoming the largest shareholder in Artios Pharma.

Artios is developing DNA damage response technology to treat cancer.

Tobin says the new funds will help Artios advance its portfolio of  small molecule DDR programmes - including its lead programme - through clinical proof of concept trials.

Accesso's landmark deal with SEVEN marks strategic growth in the Saudi Market

Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) chief executive Steve Brown joins Proactive's Stephen Gunnion with details of a significant partnership with Saudi Entertainment Ventures (SEVEN). Brown noted the collaboration highlights accesso's strategy to grow its global footprint,...

24 minutes ago